Calcium channel blocker inhibits western-type diet-evoked atherosclerosis development in apoE-deficient mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 1, 2005, Pages 320-328

  Kyselovic, Jan ^a   Martinka, Peter ^a   Batova, Zuzana ^a   Gazova, Andrea ^a   Godfraind, Theophile ^b,c  

^a Physics and Informatics   (Slovakia)

^b UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; APOLIPOPROTEIN E; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; FAT; LACIDIPINE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; RENIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CALORIC INTAKE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; ENDOTHELIUM; EXPOSURE; KIDNEY INJURY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTECTION; VASODILATATION;

ACETYLCHOLINE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET; DIHYDROPYRIDINES; KIDNEY GLOMERULUS; MALE; MICE; NITRIC OXIDE; PENICILLAMINE; TUNICA MEDIA; VASOCONSTRICTION;

EID: 25644441729     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.089847     Document Type: Article

References (39)

1. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, and Luscher TF (1998) Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 95:14367-14372.
2. Bonthu S, Heistad DD, Chappell DA, Lamping KG, and Faraci FM (1997) Atherosclerosis, vascular remodeling and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol 17:2333-2340.
3. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, and Aiello RJ (1996) Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 93:10022-10027.
4. Crauwels HM, Van Hove CE, Holvoet P, Herman AG, and Bult H (2003) Plaqueassociated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI. Cardiovasc Res 59:189-199.
5. Cristofori P, Lanzoni A, Quartaroli M, Pastorino AM, Zancanaro C, Cominacini L, Gaviraghi G, and Turton J (2000) The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens 18:1429-1436.
6. d'Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC, and Katusic ZS (2001) Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21:1017-1022.
7. Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, and Richer C (2003) Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23:183-189.
8. Godfraind T (2004) Calcium Channel Blockers. Birkhaäuser Verlag AG, Basel, Switzerland.
9. Godfraind T, Miller R, and Wibo M (1986) Calcium antagonism and calcium entry blockade. Pharmacol Rev 38:321-416.
10. Goligorsky MS, Colflesh D, Gordienko D, and Moore LC (1995) Branching points of renal resistance arteries are enriched in L-type calcium channels and initiate vasoconstriction. Am J Physiol 268:F251-F257.
11. Hayek T, Oiknine J, Brook JG, and Aviram M (1994) Increased plasma and lipoprotein lipid peroxidation in apoE-deficient mice. Biochem Biophys Res Commun 201:1567-1574.
12. Henry PD (1990) Atherogenesis, calcium and calcium antagonists. Am J Cardiol 66:3I-6I.
13. Hsu YH, Chen JJ, Chang NC, Chen CH, Liu JC, Chen TH, Jeng CJ, Chao HH, and Cheng TH (2004) Role of reactive oxygen species-sensitive extracellular signal-regulated kinase pathway in angiotensin II-induced endothelin-1 gene expression in vascular endothelial cells. J Vasc Res 41:64-74.
14. Hu L, Sealey JE, Chen R, Zhou Y, Merali C, Shi Y, Laragh JH, and Catanzaro DF (2004) Nitric oxide synthase inhibition accelerates the pressor response to lowdose angiotensin II, exacerbates target organ damage and induces renin escape. Am J Hypertens 17:395-403.
15. Hwang J, Ing MH, Salazar A, Lassegue B, Griendling K, Navab M, Sevanian A, and Hsiai TK (2003) Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation. Circ Res 93:1225-1232.
16. Jiang F, Gibson AP, and Dusting GJ (2001) Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice. Eur J Pharmacol 424:141-149.
17. Kyselovic J, Krenek P, Wibo M, and Godfraind T (2001) Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Br J Pharmacol 134:1516-1522.
18. Libby P and Galis ZS (1995) Cytokines regulate genes involved in atherogenesis. Ann NY Acad Sci 748:158-170.
19. Lu X and Kassab GS (2004) Nitric oxide is significantly reduced in ex vivo porcine arteries during reverse flow because of increased superoxide production. J Physiol (Lond) 561:575-582.
20. Matsumoto T, D'Uscio LV, Eguchi D, Akiyama M, Smith LA, and Katusic ZS (2003) Protective effect of chronic vitamin C treatment on endothelial function of apolipoprotein E-deficient mouse carotid artery. J Pharmacol Exp Ther 306:103-108.
21. Muller DN, Fischli W, Clozel JP, Hilgers KF, Bohlender J, Menard J, Busjahn A, Ganten D, and Luft FC (1998) Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res 82:13-20.
22. Nakashima Y, Plump AS, Raines EW, Breslow JL, and Ross R (1994) ApoE-deficient mice develop lesions of all phases of athereosclerosis throughout the arterial tree. Arterioscler Thromb 14:133-140.
23. Napoli C, Salomone S, Godfraind T, Palinski W, Capuzzi DM, Palumbo G, D'Armiento FP, Donzelli R, de Nigris F, Capizzi RL, et al. (1999) 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke 30:1907-1915.
24. Ohkawa H, Ohishi N, and Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358.
25. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, and Breslow JL (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353.
26. Pratico D, Tangirala RK, Rader DJ, Rokach J, and FitzGerald GA (1998) Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoEdeficient mice. Nat Med 4:1189-1192.
27. Sabbatini M, Leonardi A, Testa R, Tomassoni D, Vitaioli L, and Amenta F (2002) Effects of dihydropyridine-type Ca2 antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol 39:39-48.
28. Sato J, O'Brien T, Katusic ZS, Fu A, Nygren J, Singh R, and Nair KS (2002) Dietary antioxidants preserve endothelium-dependent vasorelaxation in overfed rats. Atherosclerosis 161:327-333.
29. Schiffrin EL (2002) Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 15:115S-122S.
30. Sims C and Harvey RD (2004) Redox modulation of basal and beta-adrenergically stimulated cardiac L-type Ca(2) channel activity by phenylarsine oxide. Br J Pharmacol 142:797-807.
31. Skov K and Mulvany MJ (2004) Structure of renal afferent arterioles in the pathogenesis of hypertension. Acta Physiol Scand 181:397-405.
32. Thomas SR, Leichtweis SB, Pettersson K, Croft KD, Mori TA, Brown AJ, and Stocker R (2001) Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol 21:585-593.
33. Ursini F (1997) Tissue protection by lacidipine: insight from redox behavior. J Cardiovasc Pharmacol 30:S28-S30.
34. van Amsterdam FT, Roveri A, Maiorino M, Ratti E, and Ursini F (1992) Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Radic Biol Med 12:183-187.
35. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, and Schiffrin EL (2002) Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40:504-510.
36. Wanner C, Greiber S, Kramer-Guth A, Heinloth A, and Galle J (1997) Lipids and progression of renal disease: role of modified low density lipoprotein and lipoprotein( a). Kidney Int Suppl 63:S102-S106.
37. Weiss D, Kools JJ, and Taylor WR (2001) Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 103:448-454.
38. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, et al. (2002) Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, doubleblind, long-term trial. Circulation 106:2422-2427.
39. Zhou X, Ono H, Ono Y, and Frohlich ED (2002) N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis and inhibits apoptosis and proliferation in an L-NAME/SHR model. J Hypertens 20: 993-1000.